Fluoxetine in child and adolescent depression: Acute and maintenance treatment

Graham J. Emslie, A. John Rush, Warren A. Weinberg, Robert A. Kowatch, Tom Carmody, Taryn L. Mayes

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

The objective was to present naturalistic 1-year follow-up information of 96 child and adolescent outpatients with major depressive disorder who had been randomized in an 8-week double-blind, placebo-controlled trial of fluoxetine. Subjects were children and adolescents, ages 8-18 years, who were entered in a randomized clinical trial of fluoxetine. Following the acute treatment trial, treatment was not controlled. At 6 months and 1 year, the subjects and parents were interviewed using the Kiddie Longitudinal Interval Follow-up Evaluation (K-LIFE) for course of depression. Eighty-seven of the 96 subjects were followed for 1 year. Of these, 74 (85%) recovered from the depressive episode during that time (47 on fluoxetine, 22 on no medication, and 5 on other antidepressants or lithium). Twenty-nine of the subjects (39%) who recovered had a recurrence of depression during the 1 year follow-up, with 55% of these occurring within 6 months. Results of this study are similar to adult studies, with respect to response and recovery of depressive episodes. Most patients (85%) recover from the episode within 1 year, but approximately 40% have a recurrence within 12 months, which is a higher recurrence rate than in adults. Recovery was associated with younger age, lower severity of depressive symptoms, higher family functioning, and fewer comorbid diagnoses. Recurrence, which occurs both on and off medication, was difficult to predict, as there was little clinical data associated with recurrence in this population.

Original languageEnglish (US)
Pages (from-to)32-39
Number of pages8
JournalDepression and Anxiety
Volume7
Issue number1
DOIs
StatePublished - 1998

Fingerprint

Fluoxetine
Depression
Recurrence
Therapeutics
Major Depressive Disorder
Lithium
Antidepressive Agents
Outpatients
Randomized Controlled Trials
Parents
Placebos
Population

Keywords

  • Adolescents
  • Children
  • Depression
  • Fluoxetine
  • Recovery
  • Recurrence

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Psychology(all)
  • Clinical Psychology

Cite this

Fluoxetine in child and adolescent depression : Acute and maintenance treatment. / Emslie, Graham J.; Rush, A. John; Weinberg, Warren A.; Kowatch, Robert A.; Carmody, Tom; Mayes, Taryn L.

In: Depression and Anxiety, Vol. 7, No. 1, 1998, p. 32-39.

Research output: Contribution to journalArticle

Emslie, Graham J. ; Rush, A. John ; Weinberg, Warren A. ; Kowatch, Robert A. ; Carmody, Tom ; Mayes, Taryn L. / Fluoxetine in child and adolescent depression : Acute and maintenance treatment. In: Depression and Anxiety. 1998 ; Vol. 7, No. 1. pp. 32-39.
@article{d869e7446be943e690939e58ac5c45d7,
title = "Fluoxetine in child and adolescent depression: Acute and maintenance treatment",
abstract = "The objective was to present naturalistic 1-year follow-up information of 96 child and adolescent outpatients with major depressive disorder who had been randomized in an 8-week double-blind, placebo-controlled trial of fluoxetine. Subjects were children and adolescents, ages 8-18 years, who were entered in a randomized clinical trial of fluoxetine. Following the acute treatment trial, treatment was not controlled. At 6 months and 1 year, the subjects and parents were interviewed using the Kiddie Longitudinal Interval Follow-up Evaluation (K-LIFE) for course of depression. Eighty-seven of the 96 subjects were followed for 1 year. Of these, 74 (85{\%}) recovered from the depressive episode during that time (47 on fluoxetine, 22 on no medication, and 5 on other antidepressants or lithium). Twenty-nine of the subjects (39{\%}) who recovered had a recurrence of depression during the 1 year follow-up, with 55{\%} of these occurring within 6 months. Results of this study are similar to adult studies, with respect to response and recovery of depressive episodes. Most patients (85{\%}) recover from the episode within 1 year, but approximately 40{\%} have a recurrence within 12 months, which is a higher recurrence rate than in adults. Recovery was associated with younger age, lower severity of depressive symptoms, higher family functioning, and fewer comorbid diagnoses. Recurrence, which occurs both on and off medication, was difficult to predict, as there was little clinical data associated with recurrence in this population.",
keywords = "Adolescents, Children, Depression, Fluoxetine, Recovery, Recurrence",
author = "Emslie, {Graham J.} and Rush, {A. John} and Weinberg, {Warren A.} and Kowatch, {Robert A.} and Tom Carmody and Mayes, {Taryn L.}",
year = "1998",
doi = "10.1002/(SICI)1520-6394(1998)7:1<32::AID-DA4>3.0.CO;2-7",
language = "English (US)",
volume = "7",
pages = "32--39",
journal = "Depression and Anxiety",
issn = "1091-4269",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Fluoxetine in child and adolescent depression

T2 - Acute and maintenance treatment

AU - Emslie, Graham J.

AU - Rush, A. John

AU - Weinberg, Warren A.

AU - Kowatch, Robert A.

AU - Carmody, Tom

AU - Mayes, Taryn L.

PY - 1998

Y1 - 1998

N2 - The objective was to present naturalistic 1-year follow-up information of 96 child and adolescent outpatients with major depressive disorder who had been randomized in an 8-week double-blind, placebo-controlled trial of fluoxetine. Subjects were children and adolescents, ages 8-18 years, who were entered in a randomized clinical trial of fluoxetine. Following the acute treatment trial, treatment was not controlled. At 6 months and 1 year, the subjects and parents were interviewed using the Kiddie Longitudinal Interval Follow-up Evaluation (K-LIFE) for course of depression. Eighty-seven of the 96 subjects were followed for 1 year. Of these, 74 (85%) recovered from the depressive episode during that time (47 on fluoxetine, 22 on no medication, and 5 on other antidepressants or lithium). Twenty-nine of the subjects (39%) who recovered had a recurrence of depression during the 1 year follow-up, with 55% of these occurring within 6 months. Results of this study are similar to adult studies, with respect to response and recovery of depressive episodes. Most patients (85%) recover from the episode within 1 year, but approximately 40% have a recurrence within 12 months, which is a higher recurrence rate than in adults. Recovery was associated with younger age, lower severity of depressive symptoms, higher family functioning, and fewer comorbid diagnoses. Recurrence, which occurs both on and off medication, was difficult to predict, as there was little clinical data associated with recurrence in this population.

AB - The objective was to present naturalistic 1-year follow-up information of 96 child and adolescent outpatients with major depressive disorder who had been randomized in an 8-week double-blind, placebo-controlled trial of fluoxetine. Subjects were children and adolescents, ages 8-18 years, who were entered in a randomized clinical trial of fluoxetine. Following the acute treatment trial, treatment was not controlled. At 6 months and 1 year, the subjects and parents were interviewed using the Kiddie Longitudinal Interval Follow-up Evaluation (K-LIFE) for course of depression. Eighty-seven of the 96 subjects were followed for 1 year. Of these, 74 (85%) recovered from the depressive episode during that time (47 on fluoxetine, 22 on no medication, and 5 on other antidepressants or lithium). Twenty-nine of the subjects (39%) who recovered had a recurrence of depression during the 1 year follow-up, with 55% of these occurring within 6 months. Results of this study are similar to adult studies, with respect to response and recovery of depressive episodes. Most patients (85%) recover from the episode within 1 year, but approximately 40% have a recurrence within 12 months, which is a higher recurrence rate than in adults. Recovery was associated with younger age, lower severity of depressive symptoms, higher family functioning, and fewer comorbid diagnoses. Recurrence, which occurs both on and off medication, was difficult to predict, as there was little clinical data associated with recurrence in this population.

KW - Adolescents

KW - Children

KW - Depression

KW - Fluoxetine

KW - Recovery

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=0031810349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031810349&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1520-6394(1998)7:1<32::AID-DA4>3.0.CO;2-7

DO - 10.1002/(SICI)1520-6394(1998)7:1<32::AID-DA4>3.0.CO;2-7

M3 - Article

C2 - 9592630

AN - SCOPUS:0031810349

VL - 7

SP - 32

EP - 39

JO - Depression and Anxiety

JF - Depression and Anxiety

SN - 1091-4269

IS - 1

ER -